Data Presented at AACR Demonstrate Peregrine Pharmaceuticals' Bavituximab Induces Immune Activation in PD-L1 Negative NSCLC Tumors
20. April 2015 08:00 ET
|
Peregrine Pharmaceuticals Inc.
- Bavituximab Alone and in Combination with Docetaxel Elicit a Tumor-Specific Immune Response in PD-L1 Negative Tumors Extracted from NSCLC Patients -
- Immune Modulating Results Consistent with...
Peregrine Pharmaceuticals Announces Three Abstracts Accepted for Presentation at AACR 2015 Annual Meeting
14. April 2015 08:00 ET
|
Peregrine Pharmaceuticals Inc.
TUSTIN, Calif., April 14, 2015 (GLOBE NEWSWIRE) -- Peregrine Pharmaceuticals (Nasdaq:PPHM) (Nasdaq:PPHMP) today announced that two preclinical abstracts and one clinical translation abstract are...
Peregrine Pharmaceuticals Announces Promising Bavituximab Phase I Data Published in the Peer-Reviewed Journal Cancer Medicine in Advanced Metastatic Breast Cancer
31. März 2015 12:45 ET
|
Peregrine Pharmaceuticals Inc.
- Combination of Bavituximab and Paclitaxel Achieved an 85% Objective Response-
- Design of Phase II Clinical Trial Underway -
TUSTIN, Calif., March 31, 2015 (GLOBE NEWSWIRE) -- Peregrine...
Peregrine Pharmaceuticals Reports Third Quarter Fiscal Year 2015 Financial Results and Recent Developments
12. März 2015 16:00 ET
|
Peregrine Pharmaceuticals Inc.
- SUNRISE Phase III Lung Cancer Trial On Track to Complete Enrollment by Calendar Year-End -
- Encouraging and Consistent Data from Immuno-Oncology Development Program Continue to Support...
Peregrine Pharmaceuticals Declares Quarterly Dividend on Its Series E Convertible Preferred Stock
10. März 2015 16:00 ET
|
Peregrine Pharmaceuticals Inc.
TUSTIN, Calif., March 10, 2015 (GLOBE NEWSWIRE) -- Peregrine Pharmaceuticals, Inc. (Nasdaq:PPHM) (Nasdaq:PPHMP) today announced that its Board of Directors has declared a quarterly cash dividend...
Peregrine Pharmaceuticals to Report Third Quarter Fiscal 2015 Financial Results After Market on March 12, 2015
05. März 2015 16:00 ET
|
Peregrine Pharmaceuticals Inc.
TUSTIN, Calif., March 5, 2015 (GLOBE NEWSWIRE) -- Peregrine Pharmaceuticals, Inc. (Nasdaq:PPHM) (Nasdaq:PPHMP), a biopharmaceutical company focused on advancing bavituximab, a novel immuno-oncology...
Peregrine Pharmaceuticals to Present at the 27th Annual ROTH Conference
02. März 2015 16:00 ET
|
Peregrine Pharmaceuticals Inc.
TUSTIN, Calif., March 2, 2015 (GLOBE NEWSWIRE) -- Peregrine Pharmaceuticals, Inc. (Nasdaq:PPHM) (Nasdaq:PPHMP), a biopharmaceutical company focused on advancing bavituximab, a novel immuno-oncology...